Skip to main content

PARP Inhibitors

PARP Inhibitors Consistently Improve PFS as First-Line Maintenance in Advanced Ovarian Cancer

Prepare for Side Effects with Use of PARP Inhibitors as Upfront Maintenance

PARP Inhibitors Do Not Significantly Increase Risk for Secondary Hematologic Malignancy

The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors

The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors

The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors

PARP Inhibitors in Ovarian Cancer: Choice May Depend on Treatment Setting, Mutation Status, and Side-Effect Profile

Key Clinical and Operational Considerations in Practice-Based Dispensing of PARP Inhibitors and Other Oral Oncology Agents

Meeting Highlights

Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer

Proper Management of Toxicities Associated with PARP Inhibitors Is Essential for Optimizing Treatment Outcomes

1
2
3

Page 2 of 3
Results 11 - 20 of 23